A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults.

Lindsay E Davis Elizabeth K Pogge

Published in: High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension (2020)

PCSK9i are effective at lowering LDL-C in older adults. Tolerability was high among patients without a history of statin intolerance. PCSK9i remain high-cost medications to both insurance companies and patients in terms of cost-sharing responsibilities.

Keyphrases

low density lipoprotein
physical activity
end stage renal disease
open label
newly diagnosed
ejection fraction
prognostic factors
coronary artery disease
clinical trial
randomized controlled trial
social media
double blind
healthcare
health information
health insurance
long term care
patient reported